How Recent Drug Pricing Laws Impact Drug Discovery (H.R. 5376)
A significant section of the Inflation Reduction Act (H.R. 5376) recently signed into law was targeted at lowering public spending on prescription drugs (Subtitle B: Prescription Drug Pricing Reform). The new laws include Medicare negotiation and includes a provision that disproportionately affects small molecules which have triggered reactions throughout the industry from the extreme of…
Drug Hunter Journal Club: March 2023
There were plenty of scientific highlights from the literature that we didn’t have space for in Molecules of the Month – here’s a reader’s digest rounding up ~20 molecules of potential interest that we didn’t have space to highlight, including Pfizer’s covalent heterobifunctional BTK degrader, BMS’ brain-penetrant GSK-3β inhibitor, the discovery story of futibatinib from…
Small Molecule of the Year – 2022
We asked the global drug discovery community to nominate and vote on their favorite molecule from 2022, and the results are in. The 2022 winner, with the most overall votes across the ten finalist molecules, is BMS’ oral, deuterated allosteric TYK2 inhibitor, deucravacitinib, the first new treatment for plaque psoriasis in nearly a decade. Here,…
Where Are They Now? Recent Updates on Past Molecules of the Month
Keep up with the latest updates on past Molecules of the Month! From a Ph. III oral HIF-PH inhibitor receiving a favorable response from the EMA to an oral mutant IDH1/2 inhibitor with FIC potential having favorable Ph. III results for hard-to-treat brain tumors, read more about the recent updates in the full article! Want…
Million-Dollar Molecules: A Dual TYK2/JAK1 Inhibitor Licensed to Biohaven, an Oral IRAK4 Degrader Exclusively Licensed by Gilead, a Ph. I AT2R Inhibitor Acquired by Eli Lilly, and more
This article highlights some recent million-dollar molecules, including: Read about more million-dollar molecules from recent M&A’s, IPOs, and other fundraising from March 2023 below. Where structures are not disclosed, we show some examples from potentially related patents to illustrate what the chemical matter might look like. Want updates like this straight to your inbox? Sign…
Negative Readouts: Updates on an NMDAR PAM, an MK2 inhibitor, and a Porcupine inhibitor
This article discusses scientifically interesting molecules that have unfortunately had negative recent readouts. Aptinyx’s therapeutic approach of targeting positive allosteric modulators (PAMs) of NMDA receptors has hit another setback in Ph. II for NYX-458. The oral, twice-daily MK2 inhibitor from Aclaris Therapeutics has results from its Ph. IIa for the treatment of moderate-to-severe hidradenitis suppurativa…